A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Arcus Biosciences, Inc.
Akeso
Arcus Biosciences, Inc.
Arcus Biosciences, Inc.
Seagen Inc.
Astellas Pharma Inc
OncoSil Medical Limited
FBD Biologics Limited
Taiho Oncology, Inc.
ImmunityBio, Inc.
Merck Sharp & Dohme LLC
AbbVie
Revolution Medicines, Inc.
Enliven Therapeutics
Astellas Pharma Inc
Akeso
Bristol-Myers Squibb
ITM Solucin GmbH
Pfizer
Toray Industries, Inc
Lisata Therapeutics, Inc.
Seattle Project Corporation
Merck Sharp & Dohme LLC
Ono Pharmaceutical Co. Ltd
Ono Pharmaceutical Co. Ltd
Ono Pharmaceutical Co. Ltd